Drugs / Pradax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00868179 | Apr 2009 → Apr 2012 | venous thromboembolism | Ross Leighton | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pradax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00868179 ↗ |
| Known as | Pradax dabigatran etexilate | “Pradax dabigatran etexilate” NCT00868179 ↗ |
| Action | Inhibit | “direct thrombin inhibitor” NCT00868179 ↗ |
| Route | Oral | “ten day supply of oral Pradax.” NCT00868179 ↗ |